No difference in the overall patient group
Extension study underway; further analyses planned

Aribio's oral Alzheimer's disease drug candidate AR1001 met its primary objective in a global Phase 3 trial. Among patients who were not taking existing dementia medications, it slowed disease progression by 31% compared with placebo. The company had decided during the trial design that it would consider the objective met if the drug demonstrated efficacy in either of the two patient groups, and it met that criterion. However, among all 1,535 patients in the trial, it did not show a statistically significant difference from placebo.


Sharon Sha, a professor at Stanford University School of Medicine and the trial's principal investigator, presented the 52-week results of the global Phase 3 trial, "POLARIS-AD," on November 16 (local time) at the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston, Massachusetts. The trial included 1,535 patients from 13 countries with mild cognitive impairment or mild dementia and confirmed amyloid protein accumulation. For 52 weeks, patients took either 30 mg of AR1001 or a placebo once daily.


Screenshot of the live broadcast of the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference

Screenshot of the live broadcast of the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference

View original image

The trial was designed to assess results in two patient groups: all 1,535 patients, and 604 patients who were not taking existing dementia medications, such as acetylcholinesterase inhibitors including donepezil or memantine. Aribio separated the two groups from the randomization stage and set different thresholds for statistical significance in advance: 0.02 for the overall patient group and 0.03 for the monotherapy group. Efficacy was assessed using the Clinical Dementia Rating-Sum of Boxes (CDR-SB), which scores the severity of dementia symptoms from 0 to 18. A higher score indicates more severe symptoms.


In the monotherapy group, scores worsened by 0.44 points less in the AR1001 group than in the placebo group, representing a 31% slowdown in disease progression. In the overall patient group, the difference in scores was only 0.11 points, or 7%. "There was no statistical difference between the treatment and placebo groups in the overall patient group," Professor Sha said. "At 52 weeks, a difference from placebo emerged in the monotherapy group, and based on the CDR-SB, progression was slowed by about 31%."


The results in the monotherapy group were similar when different analytical methods were used. The slowdown in progression was 28% to 34% both when the method for handling data from patients who dropped out was changed and when the analysis was limited to patients who followed all trial procedures. Aribio had also observed a trend toward improvement among patients not taking existing dementia medications in a Phase 2 trial in 2021.


Secondary endpoints, including cognitive function (ADAS-Cog13) and ability to perform daily activities (A-IADL), showed no statistically significant difference from placebo in either patient group. Professor Sha said, "The secondary endpoints showed trends favoring AR1001."


The drug's activity in the brain was confirmed. AR1001 inhibits an enzyme called PDE5, preventing the breakdown of the signaling molecule cGMP, which is involved in protecting nerve cells. The concentration of cGMP in the cerebrospinal fluid was higher in the treatment group than in the placebo group. In the monotherapy group, levels of the tau protein marker p-tau217 in the cerebrospinal fluid also decreased. There was no change in amyloid markers. "These results were expected given how the drug works," Professor Sha said.


The incidence of serious adverse events was similar in the treatment and placebo groups, at 10.0% and 9.8%, respectively. More patients in the treatment group stopped taking the drug because of adverse events than in the placebo group: 5.2% versus 1.7%. Diarrhea (7.7%) and dizziness (6.1%) were more common in the treatment group than in the placebo group.



The results were released just three days after the data were received. "The data had just come in last Friday," Professor Sha said. "Not all biomarkers have been analyzed yet, and the analysis is ongoing." About 95% of patients who completed the 52-week trial entered an extension study to continue taking AR1001 for one year. "The extension study is ongoing, and additional analysis results will be presented at future conferences," Professor Sha said.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing